Oraya Therapeutics

Meet the Oraya Team

The Oraya team brings together scientists, physicians, and clinical innovators with years of experience in ophthalmology and medical technology. Our team has introduced landmark tools in eye care, earned patents related to X-ray technologies, set up the first-ever clinical research programs in the retinal field, and brought numerous new products successfully to market. We all share a common passion for the development of this exciting platform, the Oraya Therapy solution.

OUR MANAGEMENT TEAM INCLUDES

Jim Taylor, President and Chief Executive Officer

Jim Taylor has more than 25 years of management and technical experience and leadership in the medical device industry. He previously served as President/CEO at sector-leading companies including Carl Zeiss Meditec, Inc. (CZMI), Coherent Medical, and Ohmeda Medical Systems. At Coherent and subsequently at CZMI, he led the introduction of several landmark technologies in eye care, including Optical Coherence Tomography (OCT) imaging systems for AMD treatment and diagnosis, as well as an array of other technologies for glaucoma, refractive, and cataract applications. During his tenure at CZMI, the company grew to become one of the most well-recognized and respected leaders in the ophthalmic industry.

Mr. Taylor received his Bachelor of Science degree with honors from the United States Naval Academy and holds a Master’s degree in administrative science from Johns Hopkins University.

Ed Battle, Chief Financial Officer

Mr. Battle has more than 20 years of experience in the high tech and medical industries, spanning functions from new business development to finance and accounting, serving predominantly as the chief financial officer. Most recently, Mr. Battle served as the Chief Financial Officer for FusionOne Inc., a successful wireless software development firm focused on over-the-air back-up of cell phone content. Prior to that, Mr. Battle served as CFO of BridgePort Networks, a communication software firm focused on off-loading wireless spectrum to the WiFi network. He also served as co-founder and CFO of a software and web development firm focused on the medical education industry, and has held positions at the accounting firm of Deloitte & Touche and at the investment bank of Wood Gundy.

Mr. Battle holds a B.Sc. in engineering from Texas A&M and an MBA from The Wharton School of Business at the University of Pennsylvania.

Denis O’Shaughnessy, PhD, Vice President of Clinical Affairs

Denis O’Shaughnessy has more than 25 years of clinical, pharmaceutical, and ophthalmology experience. Prior to joining Oraya, he was Senior Vice President of Clinical Development at OPKO, Inc., and before that, Dr. O’Shaughnessy was a founding member of Eyetech Pharmaceuticals, responsible for overseeing the Macugen® development program, which resulted in the completion and successful marketing approval of this pioneering wet AMD anti-VEGF drug in just under four years. Dr. O’Shaughnessy has worked for a number of pharmaceutical companies, including Hoffman-La Roche, where he established the first-ever clinical drug research program in the retinal field, Sandoz (Novartis), Xoma, and Celltech. While at Celltech, he headed up its Clinical Research Department. Dr. O’Shaughnessy began his career as a clinical research manager in 1984, with American Cyanamid’s European regional office in London.

Dr. O’Shaughnessy received a Bachelor of Science degree in physiology and biochemistry from Queen Elizabeth College London and a PhD in physiology from the Royal Postgraduate Medical School London.

Astrid M. Berthe, Vice President, Regulatory Affairs and Quality Assurance

Astrid M. Berthe has more than 20 years of leadership experience in areas of quality systems, regulatory compliance, engineering, manufacturing operations, and regulatory affairs. Prior to joining Oraya Therapeutics, Ms. Berthe was the Vice President of Regulatory Affairs and Quality Assurance and Compliance Officer for ATS Medical. She has also held leadership positions at Baxter Healthcare, Medtronic, and Isotis Orthobiologics.

Ms. Berthe holds a Bachelor of Science degree in industrial engineering from the University of Puerto Rico, Engineering College.

Erik Chell, PhD, Chief Scientific Officer

Eric Chell has more than 15 years of scientific and technical leadership experience in the medical device category. At Oraya, his primary focus is on the implementation and dosimetry of the X-ray subsystem. Prior to joining the Oraya team, he demonstrated a strong track record of success at a number of medical imaging and radiotherapy companies including Imatron, GE Healthcare, Xoft, and Varian Medical Systems.

Dr. Chell holds a Bachelor of Arts degree in physics from Macalester College and holds a PhD in particle physics from the University of Wisconsin, Madison.

Alan Czeszynski, Senior Director, Market and Business Development

Alan Czeszynski has more than 15 years of product marketing and development leadership experience. Prior to Oraya, Mr. Czeszynski led a number of ophthalmic diagnostic product lines at Carl Zeiss Meditec, Inc., including their market-leading Optical Coherence Tomography products, which more than doubled in global sales during his tenure. He has experience bringing a broad array of products to market, including industrial X-ray imaging equipment, consumer electronics, internet infrastructure equipment, and satellite components.

Mr. Czeszynski earned a Bachelor of Science degree in engineering with honors from the United States Naval Academy, a Master of Science in engineering from the University of New Hampshire, and an MBA with honors from Santa Clara University.

Tony Moses, Vice President Global Sales and Distribution

Tony Moses has served in various domestic and international marketing and commercial roles within the ophthalmic industry for more than 30 years. Prior to joining Oraya, Tony was Vice President of Global Marketing and Sales for NeoVista, a company also exploring radiation for the treatment of wet AMD. Prior to joining NeoVista, Tony was the Strategic Marketing Director, Retina, for Carl Zeiss Meditec. In this capacity he directed a marketing team based both in California and Germany, developing global marketing strategies for the retina product line including Optical Coherence Tomography (OCT), lasers, retinal cameras, and slit lamps. His previous experience includes various successful sales and marketing management roles with IRIDEX, including the position of International Sales Director, and Storz Instrument Company.

Back To Top

Oraya Facility
© 2014 All rights reserved to Oraya Therapeutics The IRay® Radiotherapy System is an investigational device and is not available for sale in the U.S.A. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.